Graphite Bio Inc是一家临床阶段的基因编辑公司。该公司正在开发一种新的疗法,以治疗一系列严重和危及生命的疾病。该公司的基因编辑平台可以纠正突变,用正常基因替换整个致病基因,或者将新基因插入预定的安全位置。该公司的主要候选产品GPH101是一种差异化的方法,有可能直接纠正导致镰状细胞病的突变,并恢复正常成人血红蛋白(HgbA)的表达。其管道包括多个项目,如针对β地中海贫血的GPH102和针对X连锁严重联合免疫缺陷综合征(XSCID)的GPH201,后者是其基因替代技术;GPH301用于高切病,以及针对α-1抗胰蛋白酶(AAT)缺乏症的早期研究项目(这是其靶向基因插入技术),以及造血干细胞(HSC)和其他细胞类型的多个未公开的项目。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Jeffrey P. George | Independent Chairman | 2024 | 52 |
| Evert B. Schimmelpennink | President, CEO, Secretary & Director | 2021 | 54 |
| James W. McCollum | Co-Founder & Director | 2024 | 71 |
| Frederic Guerard | Independent Director | 2024 | 53 |
| Shelley B. Thunen | Independent Director | 2024 | 72 |
| John Doane | Member of Medical Advisory Board | - | - |
| Steven J. Dell | Member of Medical Advisory Board | - | - |
| Colman Kraff | Member of Medical Advisory Board | - | - |
| Robert H. Osher | Member of Medical Advisory Board | - | - |
| Zachary Scheiner | Independent Director | 2020 | 49 |
| Deepinder K. Dhaliwal | Member of Medical Advisory Board | - | - |
| Kathryn Hatch | Member of Medical Advisory Board | - | - |
| Kimberlee Cobleigh Drapkin | Independent Director | 2023 | 58 |
| S. Barry Eiden | Member of Advisory Board | - | - |
| Andrew Morgenstern | Member of Advisory Board | - | - |
| Carolyn Majcher | Member of Advisory Board | - | - |
| Louise Sclafani | Member of Advisory Board | - | - |
| Stephanie Woo | Member of Advisory Board | - | - |
| Michael Kling | Member of Advisory Board | - | - |